Lundbeck is making a big push on the company’s capital reallocation initiative, handing over its operations in 27 markets to partners. More: Lundbeck, in major resource reallocation, bows out of 27 markets and lays off 602 staffers Source: fierce
read moreRegeneron and Sandoz have reached a settlement that resolves all patent litigation related to the Swiss company’s biosimilar version of eye disease drug Eylea. More: With settlement, Sandoz can launch its biosimilar to Regeneron's Eylea by end of 2026 Source:
read moreThe private equity firm is looking to attract other private equity buyers to take on the CDMO for a valuation of up to $4 billion, the Financial Times reported on Sept. 6. More: Permira looks to launch B sale of
read more
New partnership aims to fast-track mRNA therapies from lab to clinic More: Quotient Sciences and CPI launch RNA drug development venture Source: News
read more
First patient enrolled in AZURE-2 study comparing brelovitug to Hepcludex More: Bluejay begins phase 3 trial of brelovitug for hepatitis D Source: News
read moreSamsung Biologics has secured a contract manufacturing deal to run through Dec. 31, 2029, which will net the CDMO 1.8 trillion Korean won (roughly $1.3 billion). Samsung Bio noted that the contract timeline could be changed in the future. More:
read more© 1994 - 2026 B.M. Pharmaceuticals